Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRx in Osteoarthritis
NCT05147675Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloRx in osteoarthritis (OA) and Osteoarthritis of the Spine, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Started Dec 2022; status: recruiting.
02
Drugs
AlloRx
03
Conditions
osteoarthritis (OA)Osteoarthritis of the Spine
Beyond the preview
Go deeper on NCT05147675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147675.